B effector cells in rheumatoid arthritis and experimental arthritis

Autoimmunity

Volumn 45, Issue 5, 2012, Pages 353-363

  Finnegan, Alison ^a   Ashaye, Susan ^a   Hamel, Keith M ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Autoantibodies; B cells; Co stimulation; Rheumatoid Arthritis; T cells

Indexed keywords

AUTOANTIBODY; CYTOKINE;

ANTIGEN PRESENTING CELL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; EFFECTOR CELL; IMMUNOLOGICAL TOLERANCE; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIGEN-PRESENTING CELLS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; CYTOKINES; HUMANS; IMMUNE TOLERANCE;

EID: 84863439044     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.665526     Document Type: Article

References (111)

1. Franklin EC, Holman HR, Muller-Eberhard HJ, et al. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med 1957;105(5):425-438.
2. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete Blymphocytes.Rheumatology(Oxford) 2001;40(2):205-211.
3. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003;301(5638):1374-1377.
4. Goodnow CC, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334(6184):676-682.
5. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989;337(6207):562-566.
6. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993;177(4): 1009-1020.
7. Fulcher DA, Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med 1994;179(1):125-134.
8. Samuels J, Ng YS, Coupillaud C, et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201(10):1659-1667.
9. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201(5):703-711.
10. Wang H, Clarke SH. Evidence for a ligand-mediated positive selection signal in differentiation to a mature B cell. J Immunol 2003;171(12):6381-6388.
11. Wang LD, Lopes J, Cooper AB, et al. Selection of B lymphocytes in the periphery is determined by the functional capacity of the B cell antigen receptor. Proc Natl Acad Sci USA 2004;101(4):1027-1032.
12. Yurasov S, Tiller T, Tsuiji M, et al. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 2006;203(10):2255-2261.
13. Menard L, Samuels J, Ng YS, et al. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum 2011; 63(5): 1237-1245.
14. McLean AR, Rosado MM, Agenes F, et al. Resource competition as a mechanism for B cell homeostasis. Proc Natl Acad Sci USA 1997;94(11):5792-5797.
15. De Boer RJ, Freitas AA, Perelson AS. Resource competition determines selection of B cell repertoires. J Theor Biol 2001; 212(3):333-343.
16. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994;371(6496): 389-395.
17. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293(5537): 2111-2114.
18. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285(5425):260-263.
19. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189(11):1747-1756.
20. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190(11): 1697-1710.
21. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293(5537):2108- 2111.
22. Rahman ZS, Rao SP, Kalled SL, et al. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003; 198(8):1157-1169.
23. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20(4):441-453.
24. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20(6):785-798.
25. Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115(11): 3083-3092.
26. Pers JO, Daridon C, Devauchelle V, et al. BAFF over-expression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-39.
27. Moura RA, Cascao R, Perpetuo I, et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 2011;50(2):278-282.
28. Gottenberg JE, Miceli-Richard C, Ducot B, et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009;11(4):R114.
29. Moura RA, Weinmann P, Pereira PA, et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford) 2010;49(6):1082-1092.
30. Souto-Carneiro MM, Mahadevan V, Takada K, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009;11(3): R84.
31. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54(3):723-732.
32. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8(6):R167.
33. Nakajima K, Itoh K, Nagatani K, et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007;36(5): 365-372.
34. Masson-Bessiere C, Sebbag M, Durieux JJ, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000;119(3):544-552.
35. Daridon C, Burmester GR, Dorner T. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr Opin Rheumatol 2009;21(3):205-210.
36. Vidard L, Kovacsovics-Bankowski M, Kraeft SK, et al. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 1996;156(8):2809-2818.
37. Lanzavecchia A, Bove S, Specific B. lymphocytes efficiently pick up, process and present antigen to T cells. Behring Inst Mitt 1985;(77):82-87.
38. Abbas AK, Haber S, Rock KL. Antigen presentation by hapten-specific B lymphocytes. II. Specificity and properties of antigen-presenting B lymphocytes, and function of immunoglobulin receptors. J Immunol 1985;135(3): 1661-1667.
39. Hamel K, Doodes P, Cao Y, et al. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J Immunol 2008;180(7): 4994-5003.
40. Bouaziz JD, Yanaba K, Venturi GM, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4 + T cell activation in mice. Proc Natl Acad Sci USA 2007;104(52): 20878-20883.
41. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011;63(6):1507-1516.
42. O'Neill SK, Shlomchik MJ, Glant TT, et al. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005;174(6):3781-3788.
43. Weyand CM, Goronzy JJ, Takemura S, et al. Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res 2000;2(6): 457-463.
44. Monach PA, Hueber W, Kessler B, et al. A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci USA 2009;106(37):15867- 15872.
45. Jenkins MK, Taylor PS, Norton SD, et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147(8): 2461-2466.
46. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173(3):721-730.
47. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366(6450): 76-79.
48. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265(5176):1225-1227.
49. Lenschow DJ, Sperling AI, Cooke MP, et al. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol 1994; 153(5):1990-1997.
50. Khoury SJ, Akalin E, Chandraker A, et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995;155(10):4521-4524.
51. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174(3):561-569.
52. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009;229(1): 307-321.
53. Valle A, Aubry JP, Durand I, et al. IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Int Immunol 1991;3(3):229-235.
54. Constant S, Schweitzer N, West J, et al. B lymphocytes can be competent antigen-presenting cells for priming CD4 + T cells to protein antigens in vivo. J Immunol 1995;155(8): 3734-3741.
55. Stack RM, Lenschow DJ, Gray GS, et al. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol 1994;152(12):5723-5733.
56. Tellander AC, Pettersson U, Runstrom A, et al. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease. J Autoimmun 2001;17(1):39-50.
57. Iwai H, Kozono Y, Hirose S, et al. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol 2002;169(8): 4332-4339.
58. Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996;26(10):2320-2328.
59. O'Neill SK, Cao Y, Hamel KM, et al. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol 2007;179(8): 5109-5116.
60. Barrett TB, Shu G, Clark EA. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol 1991;146(6):1722-1729.
61. Yellin MJ, Sinning J, Covey LR, et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153(2):666-674.
62. Lumsden JM, Williams JA, Hodes RJ. Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo. J Immunol 2003; 170(2):781-787.
63. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-548.
64. Schroder AE, Greiner A, Seyfert C, et al. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996;93(1):221-225.
65. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167(2):1072-1080.
66. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006;6(3): 205-217.
67. Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005;35(5): 1347-1359.
68. Page G, Miossec P. Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol 2004;204(1):28-38.
69. Gregorio A, Gambini C, Gerloni V, et al. Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford) 2007;46(2):308-313.
70. Timmer TC, Baltus B, Vondenhoff M, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 2007;56(8): 2492-2502.
71. Luther SA, Lopez T, Bai W, et al. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000;12(5): 471-481.
72. Wengner AM, Hopken UE, Petrow PK, et al. CXCR5-and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum 2007; 56(10):3271-3283.
73. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004;172(6):3422-3427.
74. Anolik JH, Ravikumar R, Barnard J, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008;180(2):688-692.
75. Canete JD, Celis R, Moll C, et al. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68(5):751-756.
76. Manser T. Textbook germinal centers? J Immunol 2004; 172(6):3369-3375.
77. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hyper-mutation. Annu Rev Immunol 2002;20:165-196.
78. Gause A, Gundlach K, Zdichavsky M, et al. The B lymphocyte in rheumatoid arthritis: analysis of rearranged V kappa genes from B cells infiltrating the synovial membrane. Eur J Immunol 1995;25(10):2775-2782.
79. Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009; 6(1):e1.
80. Rosengren S, Wei N, Kalunian KC, et al. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008;10(5):R105.
81. Kim HJ, Krenn V, Steinhauser G, et al. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 1999;162(5): 3053-3062.
82. Aarvak T, Natvig JB. Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis. Arthritis Res 2001;3(1):13-17.
83. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167(8):4710-4718.
84. Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial) 1: clinical and synovial biomarker results. Ann Rheum Dis 2008;67(3):402-408.
85. Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009;68(6):1011-1016.
86. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68(7):1220-1227.
87. Catalan D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther 2010;12(2):R68.
88. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10(4):236-247.
89. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nature Immunol 2000;1:475-481.
90. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today 1997;18(7):343-350.
91. Yeo L, Toellner KM, Salmon M, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011;70(11): 2022-2028.
92. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68(2):216-221.
93. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3(10):944-950.
94. Mauri C, Gray D, Mushtaq N, et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197(4): 489-501.
95. Mizoguchi A, Mizoguchi E, Takedatsu H, et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002;16(2):219-230.
96. Evans JG, Chavez-Rueda KA, Eddaoudi A, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007;178(12):7868-7878.
97. Yanaba K, Bouaziz JD, Haas KM, et al. A regulatory B cell subset with a unique CD1dhiCD5 + phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28(5):639-650.
98. Yanaba K, Bouaziz JD, Matsushita T, et al. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009;182(12):7459-7472.
99. Blair PA, Norena LY, Flores-Borja F, et al. CD19(+) CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010;32(1): 129-140.
100. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117(2): 530-541.
101. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48(10):2741-2749.
102. Hueber W, Kidd BA, Tomooka BH, et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005;52(9):2645-2655.
103. Kouskoff V, Korganow AS, Duchatelle V, et al. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87(5):811-822.
104. Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. J Exp Med 1983;158(2):378-392.
105. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16(2):157-168.
106. Hietala MA, Jonsson IM, Tarkowski A, et al. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol 2002;169(1):454-459.
107. Kaplan CD, O'Neill SK, Koreny T, et al. Development of Inflammation in Proteoglycan-Induced Arthritis Is Dependent on FcgammaR Regulation of the Cytokine/Chemokine Environment. J Immunol 2002;169(10): 5851-5859.
108. Kaplan CD, Cao Y, Verbeek JS, et al. Development of proteoglycan-induced arthritis is critically dependent on Fcgamma receptor type III expression. Arthritis Rheum 2005;52(5):1612-1619.
109. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002;16(3):391-402.
110. van Lent PL, Nabbe K, Blom AB, et al. Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol 2001;159(6): 2309-2320.
111. Diaz de Stahl T, Andren M, Martinsson P, et al. Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol 2002;32(10): 2915-2922.